ストックスクリーナーアプリを入手
2.20
2.22%
-0.05
前日終値:
$2.25
開ける：
$2.24
24時間の取引高:
10.59M
Relative Volume:
0.79
時価総額：
$873.33M
収益：
$241.53M
当期純損益:
$-389.92M
株価収益率:
-1.7886
EPS:
-1.23
ネットキャッシュフロー:
$-323.54M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
-13.39%
6か月 パフォーマンス:
-4.76%
1年 パフォーマンス:
-72.36%
1日の値動き範囲:
$2.17
$2.26
1週間の範囲:
$2.16
$2.34
52週間の値動き範囲:
$1.6385
$8.15
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
名前
Iovance Biotherapeutics Inc
セクター
電話
(650) 260-7120
住所
825 INDUSTRIAL ROAD, SAN CARLOS
IOVA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.20 | 893.18M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-15 | ダウングレード | Goldman | Neutral → Sell |
| 2025-05-16 | ダウングレード | UBS | Buy → Neutral |
| 2025-05-12 | ダウングレード | Truist | Buy → Hold |
| 2025-05-09 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-07-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 開始されました | Goldman | Buy |
| 2023-09-18 | 繰り返されました | Barclays | Overweight |
| 2023-05-30 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-27 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-08-18 | 再開されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Stifel | Hold → Buy |
| 2021-12-07 | 再開されました | Cowen | Outperform |
| 2021-06-10 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | ダウングレード | Stifel | Buy → Hold |
| 2021-05-03 | 開始されました | Truist | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2021-03-08 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 開始されました | Mizuho | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-04-29 | 開始されました | Piper Jaffray | Overweight |
| 2019-02-28 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-02-07 | 開始されました | Robert W. Baird | Outperform |
| 2018-12-31 | 再開されました | B. Riley FBR | Buy |
| 2018-07-06 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-04-10 | アップグレード | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 繰り返されました | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-01 | 繰り返されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Iovance Biotherapeutics Inc (IOVA) 最新ニュース
What analysts say about Iovance Biotherapeutics Inc 2LB stockLong-Term Investment Plans & Advanced Stock Screening Tools - earlytimes.in
Iovance Biotherapeutics Stock: Analyzing Its Surprising Surge - StocksToTrade
Will Iovance Biotherapeutics’ Stock Surge? - timothysykes.com
Iovance Biotherapeutics: A Surge or A Signal to Watch? - timothysykes.com
Iovance Biotherapeutics (IOVA): Is the Market Overlooking a Potential Rebound in Valuation After a Tough Year? - Yahoo Finance
Weighing Iovance Biotherapeutics After a 71.8% Slide and DCF Upside in 2025 - Yahoo Finance
With Iovance Biotherapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - Finviz
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
What earnings margins imply for Iovance Biotherapeutics Inc. (2LB) stockWeekly Stock Analysis & Fast Momentum Stock Entry Tips - Newser
Why Iovance Biotherapeutics Inc. (2LB) stock benefits from AI revolutionJuly 2025 PostEarnings & Safe Capital Investment Plans - Newser
What technical charts say about Iovance Biotherapeutics Inc. stock2025 Price Action Summary & Reliable Entry Point Trade Alerts - Newser
Will Iovance Biotherapeutics Inc. stock recover faster than peersWeekly Stock Summary & Verified Entry Point Signals - Newser
How buyback programs support Iovance Biotherapeutics Inc. (2LB) stockInsider Selling & Free Verified High Yield Trade Plans - Newser
Why Iovance Biotherapeutics Inc. (2LB) stock is upgraded to buyMarket Activity Recap & Daily Technical Forecast Reports - Newser
What dividend safety rating applies to Iovance Biotherapeutics Inc. (2LB) stock2025 Earnings Surprises & Weekly Return Optimization Alerts - Newser
Cash per share of Iovance Biotherapeutics Inc – DUS:2LB - TradingView
Why Iovance Biotherapeutics Inc. (2LB) stock is listed among top recommendationsChart Signals & Community Trade Idea Sharing Platform - Newser
Is Iovance Biotherapeutics Inc. (2LB) stock ideal for retirement investors2025 Fundamental Recap & Precise Trade Entry Recommendations - Newser
Officer Graf Finckenstein Acquires 6,247 Of Iovance Biotherapeutics Inc [IOVA] - TradingView
Officer Puri Acquires 3,002 Of Iovance Biotherapeutics Inc [IOVA] - TradingView
Iovance Biotherapeutics (NASDAQ: IOVA) officer reports RSU vesting and tax withholding on Form 4 - Stock Titan
Why Iovance Biotherapeutics Inc. stock remains undervaluedJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - Newser
Iovance Biotherapeutics Stock Hits Day Low of $2 Amid Price Pressure - Markets Mojo
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.9%What's Next? - MarketBeat
FINAL REMINDER IOVA DEADLINE: Bronstein, Gewirtz & Grossman LLC A - The National Law Review
Class Action Lawsuit Filed: Iovance Biotherapeutics, Inc. (IOVA)Join by July 14, 2025Contact Levi & Korsinsky - The National Law Review
Iovance Biotherapeutics Stock Dips Amid Market Reactions - StocksToTrade
Virtus Investment Advisers LLC Increases Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights
Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc - The National Law Review
IOVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Iovance Biotherapeutics, Inc. (IOVA) Class Action Lawsuit: Levi - The National Law Review
Kennondale Capital Management LLC Invests $384,000 in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Iovance’s Tumultuous Journey: Positive Drug Trials Amidst Financial Turbulence - StocksToTrade
Iovance Biotherapeutics: Several Positives, But Competition Still Threatens (NASDAQ:IOVA) - Seeking Alpha
Barclays Boosts IOVA Price Target to $9, Maintains Overweight Ra - GuruFocus
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Is Iovance Biotherapeutics Inc. stock gaining market shareWall Street Watch & Risk Managed Investment Signals - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock remains stable2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock gets analyst attentionJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com
What technical patterns form on Iovance Biotherapeutics Inc. (2LB) stock charts - newser.com
How Iovance Biotherapeutics Inc. (2LB) stock compares with market leadersMarket Movement Recap & AI Based Buy and Sell Signals - newser.com
Quantitative breakdown of Iovance Biotherapeutics Inc. recent moveGlobal Markets & High Accuracy Swing Entry Alerts - newser.com
Iovance Biotherapeutics Inc (IOVA) 財務データ
収益
当期純利益
現金流量
EPS
Iovance Biotherapeutics Inc (IOVA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Dec 01 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
114,198 |
| BILINSKY IGOR | Chief Operating Officer |
Dec 02 '25 |
Option Exercise |
0.00 |
3,516 |
0 |
107,530 |
| BILINSKY IGOR | Chief Operating Officer |
Dec 01 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
108,478 |
| Vogt Frederick G | Interim CEO & General Counsel |
Dec 02 '25 |
Option Exercise |
0.00 |
10,417 |
0 |
468,948 |
| Vogt Frederick G | Interim CEO & General Counsel |
Dec 01 '25 |
Option Exercise |
0.00 |
41,669 |
0 |
476,232 |
| Puri Raj K. | Chief Regulatory Officer |
Dec 01 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
218,326 |
| Vogt Frederick G | Interim CEO & General Counsel |
Sep 02 '25 |
Option Exercise |
0.00 |
52,086 |
0 |
456,690 |
| Puri Raj K. | Chief Regulatory Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
5,470 |
0 |
215,324 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,697 |
0 |
111,857 |
| BILINSKY IGOR | Chief Operating Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,306 |
0 |
105,939 |
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):